New England Venture Capital Association recognized Gunderson Dettmer client Affinivax’s sale to GSK for $3.3B as the Life Science Deal of the Year (2022) in its 10^th annual NEVY Awards. This award honors the top New England investors and entrepreneurs across Technology, Life Sciences, Healthcare and MedTech sectors committed to leveraging science and technology for a better tomorrow. The NEVYs honor both early- and late-stage companies, as well as the venture capitalists who support them.

In the announcement of the awards, NEVCA Executive Director Ari Glantz said, “It’s a great honor to bring this community together every year in celebration. Unlike Alice’s Wonderland, the time has not stood still here in New England. We’ve matured into a premier ecosystem for entrepreneurs and investors, a maturation that was evident last night as we looked back across the decade. Ours have certainly been ten years of overwhelming resilience and growth, and 2022 exemplified that perhaps more than any past year.”

Company
Affinivax